Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
GSK Strikes Deals With Vernalis, Nabi
by Michael McCoy
August 17, 2009
| A version of this story appeared in
Volume 87, Issue 33
GlaxoSmithKline will collaborate with Vernalis to develop drugs that act against an undisclosed oncology target. Under the deal, Vernalis will receive $6 million up front and could get milestone payments exceeding $200 million. Vernalis will apply its structure-based drug-design technique to advance small-molecule drug candidates. Separately, GSK has acquired Nabi Pharmaceuticals’ PentaStaph for up to $45 million. PentaStaph is a vaccine being developed against Staphylococcus aureus, a multi-drug-resistant bacterium.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X